侵袭性淋巴瘤。
Aggressive lymphomas.
机构信息
Metabolism Branch, National Cancer Institute, Bethesda, MD 20892, USA.
出版信息
N Engl J Med. 2010 Apr 15;362(15):1417-29. doi: 10.1056/NEJMra0807082.
Abstract
Genomewide molecular profiling has revealed new subtypes of lymphoma that originate from lymphocytes that differ in developmental stage and that use distinct oncogenic programs, yet are indistinguishable under the microscope. In this review, we discuss recent progress in the molecular genetics of aggressive lymphomas and focus on the most common form of this disease, diffuse large-B-cell lymphoma, which accounts for 30 to 40% of newly diagnosed lymphomas.
摘要
全基因组分子谱分析揭示了新的淋巴瘤亚型，这些淋巴瘤起源于在发育阶段不同且使用不同致癌程序的淋巴细胞，但在显微镜下无法区分。在这篇综述中，我们讨论了侵袭性淋巴瘤分子遗传学的最新进展，并重点介绍了该病最常见的形式，即弥漫性大 B 细胞淋巴瘤，占新诊断淋巴瘤的 30%至 40%。
相似文献
1
Aggressive lymphomas.
N Engl J Med. 2010 Apr 15;362(15):1417-29. doi: 10.1056/NEJMra0807082.
2
Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome.
J Invest Dermatol. 2017 Sep;137(9):1831-1833. doi: 10.1016/j.jid.2017.06.013.
3
AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
Leuk Lymphoma. 2015;56(9):2674-82. doi: 10.3109/10428194.2014.995647. Epub 2015 Jan 21.
4
Nuclear factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type.
J Invest Dermatol. 2014 Jan;134(1):290-292. doi: 10.1038/jid.2013.265. Epub 2013 Jun 13.
5
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.
6
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Blood. 2016 Dec 29;128(26):3083-3100. doi: 10.1182/blood-2016-05-715094. Epub 2016 Oct 19.
7
B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Eur J Haematol. 2015 Mar;94(3):193-205. doi: 10.1111/ejh.12427. Epub 2014 Sep 13.
8
Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma.
Leukemia. 2007 Dec;21(12):2563-6. doi: 10.1038/sj.leu.2404844. Epub 2007 Jun 28.
9
c-Myc dysregulation is a co-transforming event for nuclear factor-κB activated B cells.
Haematologica. 2017 May;102(5):883-894. doi: 10.3324/haematol.2016.156281. Epub 2017 Feb 23.
10
Novel targeted therapies in diffuse large B-cell lymphoma.
Semin Hematol. 2015 Apr;52(2):126-37. doi: 10.1053/j.seminhematol.2015.01.007. Epub 2015 Jan 19.
引用本文的文献
1
LNS-8801 as a therapeutic agent for aggressive lymphomas: ROS-induced cytotoxicity and synergy with existing therapies.
Blood Adv. 2025 Jul 8;9(13):3310-3314. doi: 10.1182/bloodadvances.2025016199.
2
Prognostic role of interim PET-CT demonstrating partial metabolic response in diffuse large B-Cell lymphoma: a retrospective study.
Ann Hematol. 2025 Apr 17. doi: 10.1007/s00277-025-06368-0.
3
Inextricable association of connective tissue disease with B‑cell lymphoma (Review).
Mol Clin Oncol. 2025 Apr 1;22(6):48. doi: 10.3892/mco.2025.2843. eCollection 2025 Jun.
4
Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review.
Discov Oncol. 2025 Feb 15;16(1):184. doi: 10.1007/s12672-025-01958-w.
5
Prognostic model based on M2 macrophage-related signatures for predicting outcomes, enhancing risk stratification, and providing therapeutic insights in diffuse large B-cell lymphoma.
Heliyon. 2024 Dec 9;10(24):e41007. doi: 10.1016/j.heliyon.2024.e41007. eCollection 2024 Dec 30.
6
Quantitative modeling of signaling in aggressive B cell lymphoma unveils conserved core network.
PLoS Comput Biol. 2024 Oct 1;20(10):e1012488. doi: 10.1371/journal.pcbi.1012488. eCollection 2024 Oct.
7
Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC.
Cell Commun Signal. 2024 Aug 27;22(1):415. doi: 10.1186/s12964-024-01782-9.
8
Advances in biology, diagnosis and treatment of DLBCL.
Ann Hematol. 2024 Sep;103(9):3315-3334. doi: 10.1007/s00277-024-05880-z. Epub 2024 Jul 17.
9
B-cell non-Hodgkin lymphomas.
Lancet. 2024 May 4;403(10438):1791-1807. doi: 10.1016/S0140-6736(23)02705-8. Epub 2024 Apr 10.
10
Blocking Superantigen-Mediated Diseases: Challenges and Future Trends.
J Immunol Res. 2024 Jan 17;2024:2313062. doi: 10.1155/2024/2313062. eCollection 2024.
本文引用的文献
1
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.
2
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Blood. 2010 Apr 1;115(13):2578-85. doi: 10.1182/blood-2009-08-236471. Epub 2009 Nov 17.
3
AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations.
Mol Cell. 2009 Nov 25;36(4):631-41. doi: 10.1016/j.molcel.2009.11.007.
4
Molecular footprints of a germinal center derivation of human IgM+(IgD+)CD27+ B cells and the dynamics of memory B cell generation.
J Exp Med. 2009 Nov 23;206(12):2659-69. doi: 10.1084/jem.20091087. Epub 2009 Nov 16.
5
Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19946-51. doi: 10.1073/pnas.0907511106. Epub 2009 Nov 6.
6
Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
J Exp Med. 2009 Oct 26;206(11):2313-20. doi: 10.1084/jem.20091167. Epub 2009 Oct 19.
7
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
Blood. 2009 Oct 22;114(17):3533-7. doi: 10.1182/blood-2009-05-220095. Epub 2009 Aug 24.
8
TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.
Blood. 2009 Sep 17;114(12):2467-75. doi: 10.1182/blood-2008-12-194852. Epub 2009 Jul 16.
9
Mechanisms promoting translocations in editing and switching peripheral B cells.
Nature. 2009 Jul 9;460(7252):231-6. doi: 10.1038/nature08159.
10
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
Nature. 2009 Jun 4;459(7247):717-21. doi: 10.1038/nature07968. Epub 2009 May 3.
Zotero 插件